DUBLIN, Oct. 24,
2024 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt" or the "Company"), a global
specialty pharmaceutical company, today announced that it will
report third quarter 2024 earnings results for the period
ended September 27, 2024, on Tuesday,
November 5, 2024.
A conference call for investors will begin at 8:30 a.m. ET. The call can be accessed as
follows:
- Live Call Participant Registration (including dial-in):
https://register.vevent.com/register/BI60bb36abdb99465c9db5640f3457528a
- Audio Only Webcast Link (live and
replay): https://edge.media-server.com/mmc/p/6tqaksqg/
- At the Mallinckrodt website:
https://ir.mallinckrodt.com/
ABOUT MALLINCKRODT
Mallinckrodt is a global business consisting of
multiple wholly owned subsidiaries that develop, manufacture,
market and distribute specialty pharmaceutical products and
therapies. The Company's Specialty Brands reportable segment's
areas of focus include autoimmune and rare diseases in specialty
areas like neurology, rheumatology, hepatology, nephrology,
pulmonology, ophthalmology and oncology; immunotherapy and neonatal
respiratory critical care therapies; analgesics; and
gastrointestinal products. Its Specialty Generics reportable
segment includes specialty generic drugs and active pharmaceutical
ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a
channel of distribution of important company information, such as
press releases, investor presentations and other financial
information. It also uses its website to expedite public access to
time-critical information regarding the Company in advance of or in
lieu of distributing a press release or a filing with the U.S.
Securities and Exchange Commission ("SEC") disclosing the same
information. Therefore, investors should look to the Investor
Relations page of the website for important and time-critical
information. Visitors to the website can also register to receive
automatic e-mail and other notifications alerting them when new
information is made available on the Investor Relations page of the
website.
CONTACTS
Investor Relations
Derek
Belz
Vice President, Investor Relations
314-654-3950
derek.belz@mnk.com
Media
Michael Freitag / Aaron Palash / Aura Reinhard
/ Catherine Simon
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449
Mallinckrodt, the "M" brand
mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a
Mallinckrodt company. © 2024.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mallinckrodt-to-report-earnings-results-for-third-quarter-2024-302285276.html
SOURCE Mallinckrodt plc